Dorman Saskie, Perkins Paul
Palliative Medicine, Poole Hospital NHS Foundation Trust, Longfleet Road, Poole, UK, BH15 2JB.
Cochrane Database Syst Rev. 2010 Oct 6(10):CD006938. doi: 10.1002/14651858.CD006938.pub2.
Nausea and vomiting are common symptoms in patients with terminal illness and can be very unpleasant and distressing. There are several different types of antiemetic treatments which can be used to control these symptoms. Droperidol is an antipsychotic drug and has been used and studied as an antiemetic in the management of post-operative and chemotherapy nausea and vomiting.
To evaluate the efficacy and adverse events (both minor and serious) associated with the use of droperidol for the treatment of nausea and vomiting in palliative care patients.
We searched electronic databases including CENTRAL, MEDLINE, EMBASE, CINAHL and AMED, using relevant search terms and synonyms. The basic search strategy was ("droperidol" OR "butyrophenone") AND ("nausea" OR "vomiting"), modified for each database. The search was updated on 2 December 2009.
Randomised controlled trials (RCTs) of droperidol for the treatment of nausea or vomiting, or both, for adults receiving palliative care or suffering from an incurable progressive medical condition.
We judged the potential relevance of studies based on their titles and abstracts, and obtained studies which we anticipated might meet the inclusion criteria. We both read these to assess suitability for inclusion. Discrepancies were discussed to achieve consensus.
The search strategy identified 1664 abstracts (and 827 duplicates) of which 23 studies were obtained in full as potentially meeting the inclusion criteria. On review of the full papers, no studies were identified which met the inclusion criteria, therefore, there were no included studies in this review.
AUTHORS' CONCLUSIONS: There is insufficient evidence to advise on the use of droperidol for the management of nausea and vomiting in palliative care. Studies of antiemetics in palliative care settings are needed to identify which agents are most effective with a minimum of side effects.
恶心和呕吐是晚期疾病患者的常见症状，会给患者带来极大不适和痛苦。有几种不同类型的止吐治疗方法可用于控制这些症状。氟哌利多是一种抗精神病药物，已被用于并研究用于治疗术后和化疗引起的恶心和呕吐。
评估氟哌利多用于治疗姑息治疗患者恶心和呕吐的疗效及不良事件（包括轻微和严重不良事件）。
我们使用相关检索词和同义词检索了多个电子数据库，包括Cochrane系统评价数据库、医学期刊数据库、荷兰医学文摘数据库、护理学与健康领域数据库和联合和补充医学数据库。基本检索策略为（“氟哌利多”或“丁酰苯类”）与（“恶心”或“呕吐”），每个数据库在此基础上进行修改。检索于2009年12月2日更新。
氟哌利多治疗恶心或呕吐或两者兼治的随机对照试验，受试对象为接受姑息治疗或患有无法治愈的进行性疾病的成年人。
我们根据研究的标题和摘要判断其潜在相关性，获取预期可能符合纳入标准的研究。我们两人都阅读这些研究以评估其是否适合纳入。对存在的分歧进行讨论以达成共识。
检索策略共识别出1664篇摘要（其中827篇为重复摘要），最终获得23篇全文研究，这些研究可能符合纳入标准。在对全文进行审查时，未发现符合纳入标准的研究，因此，本综述未纳入任何研究。
尚无充分证据就氟哌利多用于姑息治疗中恶心和呕吐的管理提供建议。需要在姑息治疗环境中开展止吐药物研究，以确定哪种药物疗效最佳且副作用最小。
